Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 25 | 2025 | 871 | 3.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 9 | 2025 | 143 | 2.470 |
Why?
|
| T-Lymphocytes | 22 | 2025 | 1708 | 2.230 |
Why?
|
| Genetic Therapy | 4 | 2025 | 683 | 1.880 |
Why?
|
| Herpesvirus 4, Human | 7 | 2025 | 615 | 1.680 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2025 | 273 | 1.410 |
Why?
|
| Antigens, CD19 | 10 | 2024 | 171 | 1.370 |
Why?
|
| Hematologic Neoplasms | 4 | 2025 | 294 | 1.360 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2024 | 217 | 1.360 |
Why?
|
| Receptors, Antigen, T-Cell | 12 | 2024 | 458 | 1.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2024 | 1170 | 1.310 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2020 | 143 | 1.020 |
Why?
|
| Killer Cells, Natural | 4 | 2018 | 333 | 1.020 |
Why?
|
| Health Services Accessibility | 6 | 2025 | 658 | 0.980 |
Why?
|
| Lymphoma | 4 | 2025 | 319 | 0.970 |
Why?
|
| Leukemia | 2 | 2024 | 356 | 0.820 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 167 | 0.770 |
Why?
|
| Immunotherapy | 4 | 2025 | 740 | 0.710 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2024 | 258 | 0.650 |
Why?
|
| Poverty | 1 | 2023 | 431 | 0.610 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 132 | 0.610 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 786 | 0.590 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 628 | 0.580 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2018 | 553 | 0.560 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 263 | 0.500 |
Why?
|
| Humans | 53 | 2025 | 126923 | 0.490 |
Why?
|
| Receptors, KIR | 1 | 2015 | 8 | 0.470 |
Why?
|
| Immune Evasion | 1 | 2015 | 38 | 0.470 |
Why?
|
| Smad Proteins | 1 | 2015 | 42 | 0.470 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 459 | 0.450 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2015 | 53 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 3 | 2023 | 138 | 0.450 |
Why?
|
| Patient Safety | 1 | 2019 | 434 | 0.430 |
Why?
|
| Siblings | 1 | 2015 | 202 | 0.430 |
Why?
|
| Virus Activation | 1 | 2014 | 84 | 0.430 |
Why?
|
| Neoplasms | 6 | 2025 | 2856 | 0.420 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 258 | 0.420 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 219 | 0.400 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 445 | 0.390 |
Why?
|
| Child | 19 | 2025 | 25121 | 0.340 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 61 | 0.340 |
Why?
|
| CD5 Antigens | 2 | 2024 | 33 | 0.330 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 398 | 0.320 |
Why?
|
| Young Adult | 11 | 2024 | 9665 | 0.300 |
Why?
|
| Adolescent | 15 | 2025 | 20032 | 0.300 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2020 | 152 | 0.280 |
Why?
|
| Minority Groups | 2 | 2024 | 250 | 0.240 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 62 | 0.230 |
Why?
|
| Science | 1 | 2025 | 36 | 0.230 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 90 | 0.230 |
Why?
|
| Technology | 1 | 2025 | 69 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 679 | 0.220 |
Why?
|
| Hematology | 1 | 2024 | 40 | 0.220 |
Why?
|
| Rituximab | 1 | 2024 | 166 | 0.200 |
Why?
|
| Male | 15 | 2025 | 62623 | 0.200 |
Why?
|
| Proteome | 1 | 2025 | 273 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 152 | 0.190 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 41 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2024 | 174 | 0.190 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 631 | 0.180 |
Why?
|
| Adult | 12 | 2025 | 30463 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 142 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 946 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 534 | 0.180 |
Why?
|
| Female | 16 | 2025 | 68418 | 0.170 |
Why?
|
| Antigens, CD7 | 2 | 2018 | 11 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 337 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 325 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2021 | 171 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 439 | 0.150 |
Why?
|
| Cytokines | 4 | 2022 | 1321 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 35 | 0.150 |
Why?
|
| Vaccinia virus | 1 | 2019 | 50 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 50 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2025 | 1133 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 218 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 355 | 0.140 |
Why?
|
| United States | 4 | 2025 | 11318 | 0.130 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 68 | 0.130 |
Why?
|
| Child, Preschool | 7 | 2025 | 14357 | 0.130 |
Why?
|
| Transplantation, Homologous | 2 | 2018 | 642 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 985 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1234 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 304 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2017 | 159 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5126 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2019 | 559 | 0.120 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2014 | 2 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 23 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 210 | 0.100 |
Why?
|
| Vaccination | 1 | 2019 | 1004 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2015 | 754 | 0.100 |
Why?
|
| Immunologic Memory | 1 | 2014 | 194 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2036 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2015 | 1536 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3319 | 0.090 |
Why?
|
| Leukocytosis | 1 | 2011 | 46 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1548 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2019 | 670 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 512 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 741 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2013 | 435 | 0.080 |
Why?
|
| Biomarkers | 2 | 2017 | 3223 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 86 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3586 | 0.080 |
Why?
|
| Infant | 3 | 2025 | 12775 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12556 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 240 | 0.070 |
Why?
|
| Down Syndrome | 1 | 2011 | 200 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17026 | 0.070 |
Why?
|
| Animals | 8 | 2024 | 33111 | 0.070 |
Why?
|
| Mice | 6 | 2022 | 17627 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 106 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2017 | 4478 | 0.060 |
Why?
|
| Prognosis | 3 | 2025 | 4775 | 0.060 |
Why?
|
| Middle Aged | 6 | 2025 | 27758 | 0.060 |
Why?
|
| Aged | 5 | 2025 | 20395 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2024 | 1197 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2019 | 2397 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 283 | 0.060 |
Why?
|
| Drug Industry | 1 | 2025 | 47 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 222 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 478 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 120 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2024 | 72 | 0.050 |
Why?
|
| Mentors | 1 | 2025 | 154 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 150 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 158 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2014 | 330 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 87 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 165 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1482 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 198 | 0.050 |
Why?
|
| Informed Consent | 1 | 2025 | 337 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 222 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2023 | 536 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 765 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2022 | 570 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2022 | 309 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 406 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 175 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 172 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 3499 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 283 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 36 | 0.040 |
Why?
|
| Retroviridae | 1 | 2019 | 182 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 230 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 109 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 517 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 239 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 107 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 74 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 218 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 265 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 808 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 55 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 149 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2019 | 573 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 4442 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 253 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 223 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1811 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2019 | 890 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1418 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 45 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1227 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2014 | 5 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2014 | 11 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1056 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2014 | 16 | 0.030 |
Why?
|
| Pediatrics | 1 | 2024 | 1202 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 17 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 30 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 116 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 78 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 60 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 2013 | 22 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 190 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 180 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 133 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 219 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 783 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 521 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 792 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 756 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 652 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2895 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6681 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 5944 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2011 | 826 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 7376 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8350 | 0.010 |
Why?
|